This is particularly true with the use of renin angiotensin system inhibitors, including angiotensin-converting enzyme inhibitors (ACEi) and angiotensin-receptor blockers (ARBs) [7, 8], and more recently, with the use of some sodium-glucose cotransporter-2 (SGLT-2) inhibitors [9, 10], even in the absence of type 2 diabetes (T2D) [9]. The gene discussed is ACE; the disease is type 2 diabetes mellitus.